Enzalutamide + Tinengotinib for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Jun 2024: Trial started, NCT06457919
  2. 13 Jun 2024: Trial registered, NCT06457919

The trials

NCT06457919: A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

State
Under way
Phase
Phase 1 and Phase 2
People
50 planned
Started
4 Jun 2024
Primary completion
Jun 2027
Arms
Tinengotinib with enzalutamide
Results
None posted
  1. 4 Jun 2024: Trial started
  2. 13 Jun 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.